145 Impact of sepsis and antibiotics on the microbiome References 1. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016; 375: 2369–79. 2. McDonald D, Ackermann G, Khailova L, et al. Extreme dysbiosis of the microbiome in critical illness. mSphere 2016; 4: e00199-16. 3. Marquet K, Liesenborgs A, Bergs J et al. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care 2015; 19: 63. 4. Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Intens Care Med 2017; 43: 304–77. 5. Sullivan Å, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101–14. 6. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 2016; 65: 1906–15. 7. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science 2016; 352: 544–5. 8. Stevens V, Dumyati G, Fine LS et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53: 42–8. 9. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013; 13: 790–801. 10. Tacconelli E, De Angelis G, Cataldo MA et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Ch 2009; 53: 4264–9. 11. DiNubile MJ, Chow JW, Satishchandran V et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 2005; 49: 3217–21. 12. Baden LR, Thiemke W, Skolnik A et al. Prolonged colonization with vancomycin‐resistant Enterococcus faecium in long‐term care patients and the significance of “clearance”. Clin Infect Dis 2001; 33: 1654–60. 13. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 2016; 352: 535–8. 14. Brandl K, Plitas G, Mihu CN et al. Vancomycin-resistant enterococci exploit antibioticinduced innate immune deficits. Nature 2008; 455: 804–7. 15. Malik U, Armstrong D, Ashworth M et al. Association between prior antibiotic therapy and subsequent risk of community-acquired infections: a systematic review. J Antimicrob Chemoth 2018; 73: 287–96. 16. Prescott HC, Dickson RP, Rogers MAM et al. Hospitalization type and subsequent severe sepsis. Am J Respir Crit Care Med 2015; 192: 581–8. 17. Haak BW, Levi M, Wiersinga WJ. Microbiota-targeted therapies on the intensive care unit. Curr Opin Crit Care 2017; 23: 167–74. 18. Haak BW, Wiersinga WJ. The role of the gut microbiota in sepsis. Lancet Gastroenterol Hepatol 2017; 2: 135–43. 19. Maier L, Pruteanu M, Kuhn M et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018; 555: 623–8. 20. Singer M, Deutschman CS, Seymour CW et al. The Third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801–10. 21. Lankelma JM, van Vught LA, Belzer C et al. Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study. Intens Care Med 2017; 43: 59–68. 6
RkJQdWJsaXNoZXIy MTk4NDMw